4D Molecular Therapeutics Launches Phase 3 4FRONT-1 Trial for Wet AMD Treatment

4D Molecular Therapeutics (Nasdaq: FDMT) has officially become a Phase 3 biotechnology company with the launch of its 4FRONT-1 clinical trial, evaluating 4D-150 as a potential breakthrough treatment for wet age-related macular degeneration (wet AMD). The first patients have now been enrolled in the randomized, double-masked trial, which aims to demonstrate 4D-150’s ability to reduce treatment burden while maintaining vision.

The 4FRONT-1 trial, conducted across multiple sites in North America, compares 4D-150 to aflibercept (Eylea®), a standard anti-VEGF therapy. The primary endpoint is non-inferiority in best corrected visual acuity (BCVA) at 52 weeks, while the key secondary endpoint measures reductions in treatment burden. A second Phase 3 study, 4FRONT-2, set to launch in Q3 2025, will expand eligibility to include treatment-experienced patients. Topline results from both trials are expected in late 2027.

Dr. David Kirn, CEO of 4DMT, emphasized the potential of 4D-150 to offer long-term relief from frequent intravitreal injections, a significant challenge for wet AMD patients. Investigators, including Drs. Fuad Makkouk and Arshad Khanani, have expressed optimism based on promising data from earlier trials, highlighting 4D-150’s potential to transform the standard of care.

With 4D-150 progressing toward potential commercialization, the retina community is closely watching its impact on treatment paradigms for wet AMD and diabetic macular edema (DME).